首页 | 本学科首页   官方微博 | 高级检索  
     


Fluorine‐Containing 6,7‐Dialkoxybiaryl‐Based Inhibitors for Phosphodiesterase 10 A: Synthesis and in vitro Evaluation of Inhibitory Potency,Selectivity, and Metabolism
Authors:Dr Gregor Schwan  Dr Ghadir Barbar?Asskar  Dr Norbert Höfgen  Dr Lenka Kubicova  Dr Uta Funke  Ute Egerland  Dr Michael Zahn  Prof?Dr Karen Nieber  Dr Matthias Scheunemann  Prof?Dr Norbert Sträter  Prof?Dr Peter Brust  Prof?Dr Detlef Briel
Affiliation:1. Institut für Pharmazie, Universit?t Leipzig, Brüderstr. 34, 04103 Leipzig (Germany), Fax: (+49)?341?9736889;2. BioCrea GmbH, Meissner Str. 191, 01445 Radebeul (Germany);3. Department of Molecular Systems Biology, Faculty of Life Sciences, University of Vienna, Althanstr. 14, 1090 Vienna (Austria);4. Institut für Radiopharmazie, Forschungsstelle Leipzig, Helmholtz Zentrum Dresden‐Rossendorf, Permoserstr. 15, 04318 Leipzig (Germany);5. Institut für Bioanalytische Chemie, Universit?t Leipzig, Deutscher Platz 5, 04103 Leipzig (Germany)
Abstract:Based on the potent phosphodiesterase 10 A (PDE10A) inhibitor PQ‐10, we synthesized 32 derivatives to determine relationships between their molecular structure and binding properties. Their roles as potential positron emission tomography (PET) ligands were evaluated, as well as their inhibitory potency toward PDE10A and other PDEs, and their metabolic stability was determined in vitro. According to our findings, halo‐alkyl substituents at position 2 of the quinazoline moiety and/or halo‐alkyloxy substituents at positions 6 or 7 affect not only the compounds′ affinity, but also their selectivity toward PDE10A. As a result of substituting the methoxy group for a monofluoroethoxy or difluoroethoxy group at position 6 of the quinazoline ring, the selectivity for PDE10A over PDE3A increased. The same result was obtained by 6,7‐difluoride substitution on the quinoxaline moiety. Finally, fluorinated compounds (R)‐7‐(fluoromethoxy)‐6‐methoxy‐4‐(3‐(quinoxaline‐2‐yloxy)pyrrolidine‐1‐yl)quinazoline ( 16 a ), 19 a – d , (R)‐tert‐butyl‐3‐(6‐fluoroquinoxalin‐2‐yloxy)pyrrolidine‐1‐carboxylate ( 29 ), and 35 (IC50 PDE10A 11–65 nM ) showed the highest inhibitory potential. Further, fluoroethoxy substitution at position 7 of the quinazoline ring improved metabolic stability over that of the lead structure PQ‐10.
Keywords:3D QSAR  drug design  fluorine  phosphodiesterase   10   A  quinazolines
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号